biosig_rgb.png
BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
November 09, 2023 08:00 ET | BioSig Technologies, Inc.
Westport, CT, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Westport, CT, Nov. 9, 2023 -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to...
biosig_rgb.png
BioSig Appoints Global MedTech Leader Fred Hrkac as New Executive VP
November 07, 2023 08:00 ET | BioSig Technologies, Inc.
Westport, CT, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Westport, CT, November 7, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company...
biosig_rgb.png
BioSig’s New PURE EP™ Subscription Model Adopted by Mayo Clinic-Phoenix for World-Class Cardiac Care
November 02, 2023 08:00 ET | BioSig Technologies, Inc.
Westport, CT, Nov. 02, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company committed to delivering unprecedented accuracy and...
biosig_rgb.png
BioSig Adds Five New Patent Awards to 100+ Total Patent Portfolio Covering Digital Signal Processing Technology and AI
November 01, 2023 08:30 ET | BioSig Technologies, Inc.
Westport, CT, Nov. 01, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to delivering unprecedented accuracy and...
Stereotaxis Logo - New Tagline - Black Text.png
Abbott and Stereotaxis Technologies Used in First Integrated Procedures in the United States
October 31, 2023 08:57 ET | Stereotaxis, Inc.
Stereotaxis (NYSE: STXS) & Abbott (NYSE:ABT) announce the first patients in the US have been treated successfully utilizing combined technologies
RationalStat Logo 1.png
Heart Failure Therapeutics Market Size, Leading Players, Growth Trends, Forecasts, and Share Analysis 2023-2030 | RationalStat
September 12, 2023 06:00 ET | Rationalstat LLC
Wilmington, Delaware, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Global Heart Failure Therapeutics Market was valued at US$ 6.7 billion in 2022 and is expected to grow at a significant CAGR of 9.1% over the...
biosig_rgb.png
BioSig AI Sciences Achieves Infrastructure and Technology progress in Development of Generative AI Platform for Hospitals
August 24, 2023 10:30 ET | BioSig Technologies, Inc.
Westport, CT, Aug. 24, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to...
biosig_rgb.png
BioSig Introduces New Subscription Model for PURE EP™ Platform, Offering Quicker Access to Latest Features, Customizations
August 23, 2023 08:30 ET | BioSig Technologies, Inc.
Westport, CT, Aug. 23, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to...
biosig_rgb.png
BioSig's PURE EP™ Platform Debuts New Automated Features in First Patient Cases
August 22, 2023 08:00 ET | BioSig Technologies, Inc.
Westport, CT, Aug. 22, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to...
Imbria_Logo_Colour.png
Imbria Pharmaceuticals Completes Enrollment in the Phase 2 IMPROVE-ISCHEMIA Clinical Trial of Ninerafaxstat in Patients with Stable Angina
August 16, 2023 08:00 ET | Imbria Pharmaceuticals Inc.
– IMPROVE-ISCHEMIA, a randomized, placebo-controlled trial, with topline data expected in 4Q 2023 – – Additional Phase 2 data read-outs expected in 4Q 2023, including topline from the IMPROVE-HCM...